Abstract
Introduction: Bronchiolitis obliterans (BO) is a rare lung disease. Treatment lacks strong evidence and developing countries may have challenges in the management of the disease.
Objectives: To assess the impact of therapeutic measures instaured to our pediatric patients diagnosed with BO in the disease's course.
Methods: We conducted a retrospective study including children with BO treated in a Tunisian pulmonology department between January 2008 and December 2021. We recorded patients’ characteristics, different treatment modalities and courses of the disease.
Results: We have included 17 patients with BO mainly boys (76,5%). Mean age was 10,2 years. Mean age in the moment of diagnosis was 5,8 years [1-17 years]. Symptoms mainly consisted of cough (76%), recurrent lower respiratory infections (47%), wheezing dyspnea (47%) and exertional dyspnea (17%). An etiology was identified in 10 patients (post bone marrow transplantation (47%) and postinfectious (11%)). Patients were treated with inhaled corticosteroids (n=17), long action beta agonists (n=9), oral corticosteroids (n=6), azithromycin (n=10) and anti-leukotrienes (n=4). Mean follow-up time was 53 months. Twelve patients had > 1 exacerbations of their BO requiring their hospitalization (70%). Two patients required a hospitalization in an intensive care unit (24%). Long term oxygen therapy was indicated in 3 cases (4%). The median forced expiratory volume in 1 second, performed in 12 children, was 50% at the time of diagnosis. A declin in lung function was seen in 25% of patients.
Conclusion: Morbidity associated with BO is high. Management of this disease in pediatric patients is a challenge in the absence of recommandations. Further multicenter studies are needed.
Footnotes
Cite this article as Eur Respir J 2022; 60: Suppl. 66, 4100.
This article was presented at the 2022 ERS International Congress, in session “-”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022